课题基金 / 基金详情

Development of targeted therapeutics for ERG-expressing prostate cancers

Development of targeted therapeutics for ERG-expressing prostate cancers
开发表达 ERG 的前列腺癌靶向疗法
批准号：
344451
负责人：
Cox Michael E
金额：
$29.24万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2016
资助国家：
加拿大
项目状态：
已结题
起止时间：
2016-03-01 至 2019-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=344451&lang=en
关键词：
Animal Models Biochemistry Cell Biology Computer-Aided Design Drug Chemistry E26 Transformation-Specific Gene Family Gene Expression Metastasis Prostatic Adenocarcinoma Therapeutic Development

项目摘要

项目成果

Cox Michael E的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Half of prostate cancers have a common genetic abnormality, called TMPRSS2-ERG, which allows prostate cells to produce ERG in response to male sex hormone, testosterone. ERG is not normally made by prostate cells, but is known to be involved in cell movem
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding epigenetic regulation and modulation of cell stress responses by the cholesterol transporter, scavenger receptor-B1 as a novel target for treating advanced prostate cancer
  • 批准号：
    469855
  • 项目类别：
    Operating Grants
  • 资助金额：
    $69.66万
  • 财政年份：
    2022
  • 负责人：
    Cox Michael E
  • 依托单位：
    University of British Columbia
ERG-induced transformation of prostatic epithelial cells
  • 批准号：
    183802
  • 项目类别：
    Operating Grants
  • 资助金额：
    $7.29万
  • 财政年份：
    2008
  • 负责人：
    Cox Michael E
  • 依托单位：
    Vancouver General Hospital
海外基金